Research on lung cancer detection and treatment. Covers microbial predictors of immunotherapy, MRI detection, microplastics, and RAS-mutant drugs.
Research reveals the human microbiome's role in lung cancer immunotherapy, with specific bacterial species and metabolites showing promise as next-generation biomarkers. Higher oral microbial diversity and certain bacteria like AKK are associated with better outcomes, while others predict poorer outcomes.
Researchers found that patients with lung cancer had more detectable microplastics and higher microplastic burdens in their lung wash and tissue samples. The study suggests a link between microplastics and lung disease, with polypropylene and polyethylene being the most common types of plastic.
Daraxonrasib demonstrated durable responses in pretreated patients with RAS-mutant non-small cell lung cancer, with an objective response rate of 42% and median progression-free survival of 8.3 months. The therapy's safety profile, while notable, is considered manageable compared to chemotherapy options.
Research reveals UBE2M's critical regulatory link to inflammation and innate immune pathway in KrasG12D driven non-small cell lung cancer. Simultaneous UBE2M deletion and KrasG12D activation causes severe inflammatory TME, shortening life-span and promoting tumor growth.
A real-world observational study found no significant survival benefit from post-surgery immunotherapy in NSCLC patients with pathological complete response after neoadjuvant chemoimmunotherapy. The study suggests that these patients may already derive the maximum benefit from neoadjuvant therapy alone.
Researchers at Columbia University have discovered a new type of cell that protects lung cancers from attacks by the immune system. The new cells, called CHL1 fibroblasts, promote lung cancer by recruiting regulatory T cells to the border of the tumor.
Researchers found that radiation to the thymus during NSCLC treatment increased cancer spread and mortality risk in patients with relatively healthy thymus. Thymic health scores were associated with T-cell diversity, longevity, and cancer outcomes.
Sylvester Cancer Center has ranked #1 in Florida and #23 nationwide, thanks to discoveries of a genetic mutation that enables blood cancers to evade BTK inhibitors. Researchers are exploring new therapies and using AI to advance precision medicine.
A new preclinical study shows that combining HER3-DXd with olaparib significantly improves treatment responses in lung cancer models. The combination therapy induces irreparable DNA damage in cancer cells and stimulates the immune system to combat the disease.
A UC study found that only 15% of eligible American adults discuss lung cancer screenings with their doctors, highlighting the need for increased awareness and education about the lifesaving procedure. The study suggests that stigma and fear around lung cancer, as well as lack of information about the low-dose CT scan, may be barriers ...
A large international study suggests that age may influence lung cancer biology and could help guide more personalized treatment strategies. Younger adults with non-small cell lung cancer are significantly more likely to have genetic alterations that can be matched with targeted therapies.
The PolyU research team has developed TRUECAM, an integrated AI framework that ensures data and model trustworthiness in cancer diagnosis. The framework can assess the level of an AI's confidence in its diagnostic outputs and proactively prompts pathologists to review cases when uncertainty is high.
Multi-source data-driven machine learning is transforming lung cancer diagnosis, treatment, and prognosis by analyzing complex medical data. The review highlights the innovative applications of this technology in early screening, personalized treatment optimization, and dynamic prognostic risk stratification.
MIT researchers found that inhibiting caspase-1, an enzyme involved in lung inflammation, reduces the risk of developing tumors. The drug has already gone into clinical trials for other diseases and may be tested as a preventative measure for people at high risk for lung cancer.
A recent study covering 46 countries found that smokers are largely unaware of the cardiovascular risks associated with smoking and second-hand smoke. This knowledge gap is particularly concerning given the high number of cardiovascular deaths worldwide linked to tobacco use.
Researchers developed a new approach called SHIFTERS that uses focused ultrasound to temporarily 'light up' solid tumors, giving cancer-fighting immune cells a target they can recognize. The technology allows doctors to control where and when treatment switches on, potentially making solid tumors easier to treat.
Research at UT MD Anderson Cancer Center has identified biomarkers to identify patients with resectable NSCLC who benefit most from perioperative immunotherapy. The center also found that the composition of donor cord blood may influence CAR NK cell therapy outcomes.
Researchers found molecular signs of changes in the blood of people exposed to air pollution, detectable years before diagnosis with lung cancer. The study suggests potential biomarkers for early detection and prevention strategies.
A randomized phase 3 study found that first-line osimertinib plus chemotherapy significantly improved median progression-free survival compared to osimertinib alone in patients with advanced non–small cell lung cancer (NSCLC) and concurrent EGFR and TP53 mutations. This study provides evidence for incorporating TP53-based molecular ris...
Researchers developed a simple, fast, and low-cost blood test that identifies the tumor's biological fingerprint with over 90% accuracy. The test distinguishes between lung cancer patients and healthy individuals without DNA sequencing.
ASTRA-Net helps reconstruct overlooked peripheral airways, creating more complete maps for bronchoscopy procedures. The AI framework demonstrates strong performance in identifying fine peripheral airways and supports navigation to difficult-to-reach lung lesions.
A NIH-funded research project has generated a comprehensive collection of patient-derived tumor models, covering 25 types of cancer from thousands of donor tissues. These models closely match their parental tumors in terms of genetic alterations and gene expression signatures, enabling researchers to explore tumor evolution and diversity.
A blood test that detects circulating tumor DNA can predict whether patients with advanced non-small cell lung cancer are benefiting from immunotherapy. The test was found to be accurate in predicting therapy response and can provide clinically meaningful information weeks before conventional imaging.
Researchers found that high brain metabolism is associated with longer overall survival, and it's an independent prognostic factor for overall survival. Brain metabolism measured by ¹⁸F-FDG PET/CT provides valuable insight into patient outcomes and may help identify patients most likely to benefit from early supportive care.
Researchers discovered 171 distinct mutations causing MET exon 14 skipping in lung cancer patients. RNA-based testing confirmed these alterations, highlighting the importance of complementary diagnostic approaches.
A new study by McGill researchers provides detailed insights into how quitting smoking affects the human lung at the cellular level. Quitting appears to leave lasting changes in genes linked to tissue structure, immune function, and blood vessel health in some lung cells.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found significant sex-based protein differences in lung adenocarcinoma, with 901 proteins varying between male and female patient samples. This study contributes to understanding cancer biology and may benefit physicians and patients.
A cohort study of Korean patients with lung cancer found that international screening guidelines excluded 64.6% of patients, many without smoking history. Ineligible patients had lower mortality risk than eligible patients, suggesting tailored approaches are necessary to enhance early detection.
A new study has identified two naturally occurring microRNAs, microRNA-15a and microRNA-16, which can significantly reduce the growth and protein synthesis of non-small cell lung cancer cells. This finding suggests that these microRNAs could serve as targets for therapies designed to slow cancer progression.
The Association for Molecular Pathology recognizes Dartmouth Health medical director Laura J. Tafe for her exceptional leadership and dedication to the field of molecular diagnostics. She has been a member of the organization since 2007 and has held various positions, including president in 2023.
A buildup of bile acids caused by an unhealthy gut can drive breast cancer to other parts of the body, researchers reveal. The study found that replenishing beneficial bacteria or treating patients with FDA-approved bile acid sequestrants may reduce breast cancer metastasis.
Researchers have developed an innovative combination treatment strategy that uses cells' waste removal functions to effectively dismantle multiple myeloma. The experimental targeted protein degrader enhances the destruction of a specific cancer cell survival protein and works in tandem with existing drugs, while showing limited toxicity.
Scientists have developed a non-invasive method to predict gene changes causing lung cancer using fluorescence lifetime imaging microscopy (FLIM). This approach can identify specific genetic mutations, such as EGFR, with high accuracy and speed, preserving limited biopsy material for further analysis.
A new study reveals that lung tumors can cause cachexia by hacking into the nervous system and altering eating behavior. Researchers found that tumors missing a gene called LKB1 produced prostaglandin E2, a signaling molecule that amplifies inflammation and causes weight loss.
A study published in Cancer Cell identified a six-gene signature in microscopic colorectal cancer liver metastases that may help predict recurrence after treatment. The findings suggest these tiny tumor deposits could serve as a tissue-based marker of residual cancer cells, recurrence risk and chemotherapy resistance.
A new study by Thales Papagiannakopoulos and colleagues found that lung cancer tumors talk directly to the nervous system through sensory neurons in the lungs, promoting cachexia. Silencing these nerves or blocking the production of prostaglandin E2 (PGE2) reduced cachexia, suggesting a potential therapeutic strategy.
The respiratory microbiota drives lung cancer through four integrated pathways: oncogenic signaling, epigenetic/metabolic reprogramming, chronic immune dysregulation. Microbial signatures can predict diagnosis, staging, and therapy response.
A genomic study found two previously unreported truncating germline variants in BRCA2, suggesting inherited alterations may contribute to susceptibility to multiple primary lung cancers. The study also points toward important clinical applications, including the use of PARP inhibitors and molecularly targeted approaches for treatment.
Emerging evidence positions lactylation as a critical metabolic-epigenetic hub in lung cancer. Lactylation drives oncogenic programs and immune-evasion pathways, contributing to treatment resistance. Targeting this axis may restore treatment sensitivity.
A University of Arizona research team has developed a nanotechnology-based platform combining paclitaxel with siRNA to enhance the immune response against lung cancer. The approach exploits an 'eat me' signal on dying cancer cells, attracting immune cells and initiating tumor death.
A new study found that socioeconomic challenges hinder lung cancer screening adherence and equity, highlighting the need for targeted interventions to improve patient experience. Lower-income participants reported greater discomfort or anxiety during low-dose chest CT screening.
A phase III trial is investigating whether an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery. Researchers aim to enroll 336 participants with stage I non-small cell lung cancer and determine if the treatment reduces recurrence.
Researchers found that patients often wait an average of four weeks for biomarker test results, with the first step taking up to 23 days to order testing. This delay can lead to mismatched therapies, toxic side effects, and reduced treatment options, emphasizing the need for improved testing turnaround times.
Researchers identify CLASS 3G subtype of EGFR mutation associated with limited response to targeted drugs. This structural subtype alters protein shape, reducing treatment efficacy and allowing for more effective combination therapy.
Two new UH CPRIT grants will accelerate lung cancer prevention, diagnosis, and treatment. Researchers aim to develop new mRNA-based immunotherapies and a next-generation blood test for precise lung cancer detection.
A new national analysis found that mesothelioma deaths and diagnoses continue to rise in the US, with little improvement in survival rates. The disease disproportionately affects women and several high-risk states tied to shipbuilding, mining, and legacy asbestos exposure.
A 14-protein signature in the blood can predict lung cancer risk more than five years before diagnosis, according to researchers at the Francis Crick Institute. The team used machine learning on plasma data from over 48,000 people to identify the signature, which reflects an altered inflammatory lung environment.
Researchers analyzed tumor samples from over a thousand patients and found that TP53 gene mutations can worsen prognosis and reduce effectiveness of targeted therapies. The study suggests incorporating genetic testing into public health services to guide personalized treatment choices.
The study found that adjuvant nivolumab did not improve disease-free survival in patients with resected non–small cell lung cancer. The treatment was also not effective in sensitizing EGFR and ALK alterations.
A new study shows that targeted cancer drug selpercatinib can significantly reduce the risk of lung cancer returning in patients with a rare genetic subtype. After two years, 92% of patients remained cancer-free, compared to 61% who received a placebo.
A population-based screening trial evaluating a cell-free DNA multicancer early detection test found modest increases in diagnostic delay rates for head and neck, lung, and upper gastrointestinal cancers. These findings suggest that future trials may need to consider system-level spillover effects on healthcare resources.
A new study published in JAMA found that using a cryoprobe for lung biopsies significantly increases the diagnostic yield compared to standard forceps, with nearly 10 percentage points higher accuracy. The 1.1-millimeter cryoprobe was shown to be safer and more effective than larger probes without crushing tissue samples.
Severe obstructive sleep apnea is associated with higher lung cancer incidence and mortality, driven by mechanisms such as HIF activation, immune remodeling, and enhanced cancer stem cell properties. Long-term adherent CPAP therapy shows promise in mitigating these risks.
The WU-KONG28 trial found that sunvozertinib significantly extended progression-free survival to over 10 months, compared to 7.5 months with chemotherapy alone. The treatment also shrank tumors in 58.9% of patients.
Researchers from Ohio State University Comprehensive Cancer Center present new findings on a hospital program that redistributes unused oral cancer drugs donated by patients. The program helps patients avoid treatment delays caused by insurance issues, shipping problems or cost, and has been shown to reduce drug delays by six days.
Researchers discovered lung cancer cells change identity to resist treatment by reactivating a process involved in early lung development. This could help doctors predict which patients respond well to treatment and provide personalized care.
Researchers discovered that degrading mutant KRAS protein leads to greater lung cancer regression and more durable antitumor responses than conventional inhibitors. The study also identifies resistance mechanisms distinct from those previously described, offering new insights into targeted protein degradation therapies.
Researchers from Mass General Brigham Cancer Institute presented various studies on cancer treatments, including the efficacy of lung cancer drug neladalkib and a psychosocial digital app for patients with multiple myeloma. An electronic frailty index was also used to identify high-risk older adults receiving CAR-T cell therapy.
Researchers from ECOG-ACRIN Cancer Research Group will present updated outcomes from the STAMP study on Merkel cell carcinoma, primary results from studies in glioblastoma and non-small cell lung cancer, and emerging approaches in precision oncology. AI-driven insights from the TAILORx breast cancer trial will also be showcased.
The LUNA-2 trial will pair immunotherapy with fecal microbiota transplantation (FMT) to boost treatment effectiveness in people with non-small cell lung cancer. If successful, it could provide new treatment options for those living with the disease, helping them live longer and with fewer side effects.